Femoston Low is a hormone replacement therapy that combines low dosages of steroids, i.e. 0.5 mg of estradiol and 2.5 mg of dydrogesterone. This oral preparation should be taken continuously to treat climacteric symptoms in menopausal women. Femoston Low is in agreement with the recent recommendations for menopausal hormone replacement therapy, which give the preference to low dosage therapy whenever possible. The goals are to potentially minimize the risk of breast cancer, the danger of venous or arterial thrombosis and the glucose and lipid metabolic disturbances. Nevertheless, the preparation should efficaciously oppose to endometrial hyperplasia and yield a high degree of amenorrhea.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Objective: The clinical effects of the nourishing Yin and tonifying Yang sequential method with Femoston was explored in treating circadian disorder with premature ovarian insufficiency (POI).
Method: We enrolled 600 patients with circadian disorder and POI in a prospective study and divided the patients into 2 groups: an experimental and a control group. Both groups were treated with Femoston and the experimental group also received nourishing Yin and tonifying Yang sequential method.
[Modified Dihuang Decoction improves ovarian reserve in mice by regulating Bcl-2-related mitochondrial apoptosis pathway].
Zhongguo Zhong Yao Za Zhi
December 2021
Institute of Pediatrics, Nanjing University of Chinese Medicine Nanjing 210023, China.
The present study investigated the effect of Modified Dihuang Decoction in improving ovarian reserve in mice through the Bcl-2-related mitochondrial apoptosis pathway. Forty-eight adult female BALB/c mice were randomly divided into the following six groups with eight mice in each group: a blank group, a model group, a femoston group(three cycles of treatment with 0.13 mg·kg~(-1) estradiol tablets for 2 days and 1.
View Article and Find Full Text PDFFemoston Low is a hormone replacement therapy that combines low dosages of steroids, i.e. 0.
View Article and Find Full Text PDFLow incidence of endometrial hyperplasia with acceptable bleeding patterns in women taking sequential hormone replacement therapy with dydrogesterone.
Gynecol Endocrinol
August 2000
Laboratoire Pasteur-Cerba, Cergy Pontoise, France.
A meta-analysis was undertaken to assess the incidence of endometrial hyperplasia during sequentially combined oral 17 beta-estradiol and dydrogesterone (Femoston) treatment in postmenopausal women. Bleeding pattern was assessed separately in each study. Two studies were double-blind, 6-month studies and two were open, long-term (1- or 2-year) studies.
View Article and Find Full Text PDFObjectives: To assess the effects of Femoston (2 mg micronised 17 beta oestradiol daily, sequentially combined in one tablet with 10 mg dydrogesterone for 14 days per 28 day cycle) on the serum lipid profile of postmenopausal women.
Methods: 188 healthy postmenopausal women with intact uteri (aged 40 to 65 years) were enrolled in an open, multicentre, one-year study. Serum lipids and lipoproteins were measured at baseline and after 3, 6 and 12 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!